Background Cyclophosphamide and glucocorticoids have been the cornerstone of
remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)−associated …

Background The 18-month efficacy of a single course of rituximab as compared with conventional
immunosuppression with cyclophosphamide followed by azathioprine in patients with …

Objective To refine and validate the Birmingham Vasculitis Activity Score (BVAS) as a
disease‐specific activity index for Wegener's granulomatosis (WG). Methods Sixteen members of …

Background: The American College of Rheumatology (ACR) established criteria to
discriminate among patients with seven types of vasculitis. Although designated as “classification …

Purpose: To summarize the literature on the clinical utility of antineutrophil cytoplasmic
antibody (c-ANCA) as a diagnostic marker for Wegener granulomatosis. Data Sources: A …

Background: Venous thrombotic events (VTEs) have been observed in Wegener granulomatosis,
but the incidence rate is not known. Objective: To measure the incidence of VTEs in …

Retroperitoneal fibrosis (RF) is a disease that can occur at any age, with a peak incidence
in patients 40 to 60 years of age. The characteristic finding in this disease is a periaortic …

Objective To analyze damage occurring in patients with Wegener's granulomatosis (WG)
enrolled in the WG Etanercept Trial (WGET) and to correlate that damage with disease activity, …

OBJECTIVE: To study the medical and socioeconomic impact of Wegener's granulomatosis (WG)
in a large cohort (n = 701) of patients who are members of the international WG …

Objective Etanercept is a soluble fusion protein designed to inhibit tumor necrosis factor (TNF).
During the Wegener's Granulomatosis Etanercept Trial (WGET), a placebo‐controlled …